Procore signs multi-year strategic collaboration agreement with AWS
On Thursday, BTIG analysts upheld their Buy rating and $15.00 price target for Coya Therapeutics (NASDAQ:COYA), following recent clinical trial data. The stock, currently trading at $7.11, has shown strong momentum with an 11.4% gain in the past week. According to InvestingPro data, analyst targets range from $14 to $18, suggesting significant upside potential. The data supported the effectiveness of monthly dosing of the company’s COYA301 treatment, which is a low-dose IL-2 therapy, over a bi-weekly regimen. The analysts highlighted that the new blood biomarker data continued to show anti-inflammatory effects, reinforcing the previous clinical findings.
The trial results demonstrated that monthly dosing led to better cognitive improvements and cerebrospinal fluid (CSF) biomarkers than the bi-weekly dosing. Additionally, the monthly regimen showed more significant improvements in the numbers and suppressive function of Treg cells, which are critical for disease control. While the company maintains strong liquidity with a current ratio of 15.31, InvestingPro analysis indicates the company is not yet profitable, with an EBITDA of -$11.11M in the last twelve months. The analysts noted that bi-weekly dosing appeared to activate a broader range of immune cells, beyond those with the high-affinity IL-2 receptor, which may not be beneficial for disease management.
Coya Therapeutics is expanding its research with COYA303, a combination therapy of low-dose IL-2 and a GLP-1 receptor agonist (RA). This new approach is expected to benefit from the anti-inflammatory effects of both components. The analysts believe that the therapeutic potential of GLP-1 RAs in Alzheimer’s disease (AD) has been substantially de-risked, citing recent data showing that daily injections of Liraglutide were associated with slower brain volume loss and reduced cognitive decline.
The company’s strategy aligns with the broader industry’s efforts to explore the clinical potential of GLP-1 receptor agonists in AD. Novo Nordisk (NYSE:NVO), which is not rated by BTIG, is conducting two large placebo-controlled Phase 3 studies, EVOKE and EVOKE+, to determine if GLP-1 receptor agonism can reduce cognitive decline in patients with early-stage symptomatic AD. The primary endpoint of these studies will be the change in the CDR-SB score at week 104, with primary completion expected around September 2025, as per Clinicaltrials.gov. With an overall Financial Health score of "GOOD" from InvestingPro, Coya Therapeutics appears well-positioned to execute its development strategy. Subscribers can access additional insights, including 6 more ProTips and detailed financial metrics.
In other recent news, Coya Therapeutics has been making significant strides in the field of neurodegenerative disease treatment. The biotech firm recently reported positive results from a Phase 2 Alzheimer’s disease study, indicating that low-dose interleukin-2 (LD IL-2) treatment led to significant reductions in proinflammatory markers and improvements in beta amyloid 42 clearance. Additionally, Coya is advancing COYA 303, a biologic aimed at treating inflammatory diseases, and has enrolled five subjects in a Phase 1 study for Frontotemporal Dementia (FTD) treatment.
Boral (OTC:BOALY) Capital has initiated coverage on Coya Therapeutics, assigning a Buy rating based on the company’s innovative approach to treating neurodegenerative disorders. In 2025, Coya aims to advance its lead biologic investigational product, COYA 302, through various stages of clinical development. The company plans to submit a data package to the FDA for a Phase 2 study of COYA 302 in patients with Amyotrophic Lateral Sclerosis (ALS) by the second quarter of 2025, and expects to report results from an open-label study of LD IL-2 + CTLA4-Ig in FTD in the second half of the year.
These developments are part of Coya’s strategic focus on upcoming clinical trials in neurodegenerative diseases, as highlighted by CEO Dr. Arun Swaminathan in a recent letter to shareholders. The company continues to build its intellectual property portfolio and explore opportunities for strategic partnerships as it remains committed to advancing the treatment of neurodegenerative diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.